Crinetics Pharmaceuticals, Inc. (CRNX)
84.79
+0.10
(+0.12%)
USD |
NASDAQ |
Aug 24, 16:00
84.79
0.00 (0.00%)
After-Hours: 20:00
Crinetics Pharmaceuticals EPS Diluted (Quarterly) : -1.145 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.145 |
| March 31, 2026 | -1.228 |
| December 31, 2025 | -1.292 |
| September 30, 2025 | -1.381 |
| June 30, 2025 | -1.233 |
| March 31, 2025 | -1.039 |
| December 31, 2024 | -0.8809 |
| September 30, 2024 | -0.9593 |
| June 30, 2024 | -0.9373 |
| March 31, 2024 | -0.9259 |
| December 31, 2023 | -0.895 |
| September 30, 2023 | -1.011 |
| June 30, 2023 | -0.9393 |
| March 31, 2023 | -0.8532 |
| December 31, 2022 | -0.8357 |
| September 30, 2022 | -0.7797 |
| June 30, 2022 | -0.8068 |
| March 31, 2022 | -0.7258 |
| December 31, 2021 | -0.6808 |
| Date | Value |
|---|---|
| September 30, 2021 | -0.727 |
| June 30, 2021 | -0.7041 |
| March 31, 2021 | -0.6937 |
| December 31, 2020 | -0.6567 |
| September 30, 2020 | -0.557 |
| June 30, 2020 | -0.525 |
| March 31, 2020 | -0.7089 |
| December 31, 2019 | -0.6003 |
| September 30, 2019 | -0.5961 |
| June 30, 2019 | -0.5143 |
| March 31, 2019 | -0.3742 |
| December 31, 2018 | -0.3533 |
| September 30, 2018 | -0.3791 |
| June 30, 2018 | -0.7336 |
| March 31, 2018 | -0.2285 |
| December 31, 2017 | -0.1108 |
| September 30, 2017 | -0.0996 |
| June 30, 2017 | -0.0686 |
| March 31, 2017 | -0.109 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 4.310 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
| Pfizer Inc. | -0.0435 |
| Bristol Myers Squibb Co. | 1.620 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -120.86M |
| Revenue (Quarterly) | 25.12M |
| Total Expenses (Quarterly) | 145.97M |
| Enterprise Value | 7.802B |
| Gross Profit Margin (Quarterly) | 95.12% |
| Profit Margin (Quarterly) | -481.1% |
| Earnings Yield | -5.95% |
| Normalized Earnings Yield | -5.950 |